ATTO - Attovia Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ATTO

ATTOVIA THERAPEUTICS, INC.

NASDAQ

$20.80

▲ UP 2.92% (0.59)

KEY STATISTICS

Market Cap$895.02 M

52w High$24.32

52w Low$16.15

Dividend Yield—

Frequency—

P/E—

Volume362.17K

Shares Out.43.03M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Tao Fu

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 5, 2026

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE

$20.80 ▲ UP 2.92% (+$0.59)

About Attovia Therapeutics, Inc.

https://www.attovia.com ↗

A clinical-stage biopharmaceutical company developing immune-mediated disease therapies using its ATTOBODY platform, with lead candidate ATTO-1310 targeting IL-31 for chronic pruritic conditions like atopic dermatitis.

INDUSTRY

Biotechnology

A PRODUCT ATTOVIA THERAPEUTICS, INC. IS KNOWN FOR

ATTO-1310

ATTO-1310, Attovia’s lead clinical-stage drug, targets interleukin-31 to treat severe itching and atopic dermatitis, aiming to become a best-in-class therapy for chronic pruritus.